socalTECH

OCTOBER 21, 2013

San Diego-based Arcturus Therapeutics , a developer of RNAi technology, said it has raised $5M in a Series A funding round. According to Arcturus, the funding came from multiple private capital,, high net worth investors from Canada, Japan, and the United States. Names of those capital sources were not announced.

Arcturus 153

Arcturus San Diego .Net Venture Capital 153

socalTECH

NOVEMBER 9, 2020

San Diego-based Arcturus Therapeutics has received up to $220M in additional financial commitments from the country of Singapore, after receiving positive Phase 1/2 study results on one of its compounds.

Arcturus 113

Arcturus Study San Diego Funding 113

socalTECH

JUNE 3, 2013

San Diego-based Arcturus Therapeutics , which is developing RNAi therapeutics to treat disease, said this morning that it has raised $1.3M Arcturus Therapeutics is headed by Joseph E. Arcturus Therapeutics is headed by Joseph E. arcturus therapeutics venture capital rnai lifescience biotech'

Arcturus 138

Arcturus San Diego .Net Venture Capital 138

socalTECH

JUNE 19, 2009

San Diego-based Sorrento Therapeutics , a new biotechnology startup, has raised $2.3M Dr. Schuh was previously CEO and Director of AviaraDx, and also served at Arcturus Bioscience and Sequenom. Schuh was previously CEO and Director of AviaraDx, and also served at Arcturus Bioscience and Sequenom.

Arcturus 100

Arcturus San Diego Venture Capital Equity 100

Xconomy

APRIL 17, 2020

The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol.

Equity 84

Equity Activity Marketing Company 84

Xconomy

MARCH 2, 2018

Biotech startups rolled in cash this week. By our count, investors put more than $800 million into life-sciences startups in four days. The money came from a wide range of backers, not just traditional biotech venture firms. It’s early yet in 2018, but the current count could put life-sciences companies on pace to bust past last year’s $17.6

Funding 52

Funding Report Startup Venture Capital 52